Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Robert Q. Le, Donna Przepiorka, Haiyan Chen, Yuan Li Shen, E. Dianne Pulte, Kelly Norsworthy, Marc R. Theoret, R. Angelo De Claro

Blood (2024) 144 (2): 206–215.

https://doi.org/10.1182/blood.2023023313

Published: 2024

Includes: Supplemental data

Journal Articles

Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation

Natasha A Jain, MD, Prathima Anandi, MD, Upneet Chawla, BS, MD, Sawa Ito, MD PhD, Debbie Draper, RN, Eleftheria Koklanaris, RN, Sara Hauffe, RN, Jeanine Superata, RN, Robert Q. Le, MD PhD, David Stroncek, MD, Pawel Muranski, MD, Minoo Battiwalla, MD MS, John Barrett, MD

Blood (2016) 128 (22): 4596.

https://doi.org/10.1182/blood.V128.22.4596.4596

Published: 2016

Journal Articles

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Robert Q. Le, MD PhD, Prathima Anandi, MD, Xin Tian, PhD, Sawa Ito, MD, Natasha A Jain, MD, Meghali Goswami, Catherine E. Lai, MD, Christopher S. Hourigan, MDPhD, Sharon Adams, Nancy F. Hensel, Austin John Barrett, MDFRCP,FRCPath, Minoo Battiwalla, MD MS

Blood (2015) 126 (23): 3212.

https://doi.org/10.1182/blood.V126.23.3212.3212

Published: 2015

Journal Articles

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

Robert Q. Le, MD PhD, Xin Tian, Natasha A Jain, MD, Kit Lu, MD, Sawa Ito, MD, Debbie A Draper, RN, Prathima Anandi, MD, Christopher S. Hourigan, MDPhD, Neil Dunavin, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2014) 124 (21): 2550.

https://doi.org/10.1182/blood.V124.21.2550.2550

Published: 2014

Journal Articles

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

Ankit Anand, MD, Prathima Anandi, MD, Jain A. Natasha, MD, Kit Lu, MD, Neil Dunavin, MD, Christopher S. Hourigan, MDPhD, Robert Q. Le, MDPhD, Puja D. Chokshi, MD, Sawa Ito, MD, David F. Stroncek, MD, Marianna Sabatino, MD, John Barrett, MD, Minoo Battiwalla, MDMS

Blood (2014) 124 (21): 3898.

https://doi.org/10.1182/blood.V124.21.3898.3898

Published: 2014

Journal Articles

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Priyanka A Pophali, MD, Kamna Chawla, MD, MS, Eleftheria K. Koklanaris, BSN, Avan Antia, Simar Chawla, Sawa Ito, MD, Jeffrey K. Klotz, MD, Robert Q. Le, MD, PhD, A. John Barrett, MD, FRCP, Minoo Battiwalla, MD, MS

Blood (2011) 118 (21): 4099.

https://doi.org/10.1182/blood.V118.21.4099.4099

Published: 2011

Journal Articles

Evolution of the Donor T Cell Repertoire In Allogeneic Stem Cell Transplant Recipients In the Second Decade After Transplantation

Robert Q. Le, MD, PhD, J. Joseph Melenhorst, PhD, Brenna Hill, MPhil, Sarfraz Memon, MD, Minoo Battiwalla, MD, MS, Bipin N. Savani, MD, Aarthi Shenoy, MD, Nancy F. Hensel, BS, Eleftheria K. Koklanaris, RN, BS, Keyvan Keyvanfar, BS, Frances T. Hakim, PhD, Daniel C. Douek, MD, PhD, A. John Barrett, MD, FRCP, FRCPath

Blood (2010) 116 (21): 831.

https://doi.org/10.1182/blood.V116.21.831.831

Published: 2010

NARROW

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Evolution of the Donor T Cell Repertoire In Allogeneic Stem Cell Transplant Recipients In the Second Decade After Transplantation

Email alerts

ASH Publications

American Society of Hematology

Complete remission with partial hematological recovery as a palliative endpoint for treatment of acute myeloid leukemia

Reduced Non Relapse Mortality (NRM) and Survivable Acute Graft Versus Host Disease (GVHD) in the Current Era of Myeloablative Ex Vivo T-Cell Depleted (TCD) Transplantation

Comparison of Donor KIR Genotype, Recipient CMV Reactivation and Pretransplant MRD in Predicting Relapse after Ex Vivo T-Deplete Allohsct

Clinical Comorbidity Measures and Predictive Scores in Ex Vivo T Cell Depleted Allogeneic Hematopoietic Stem Cell Transplantation

CD34+ Selection Avoids Methotrexate and Reduces the Severity of Oral Mucositis in TBI-Based Allogeneic Stem Cell Transplantation

Chronic Graft Versus Host Disease (GVHD) Does Not Impact Cardiovascular Risk Factors in Survivors of Allogeneic Hematopoietic Stem Cell Transplantation (SCT) up to the Second Decade Post-Transplant,

Evolution of the Donor T Cell Repertoire In Allogeneic Stem Cell Transplant Recipients In the Second Decade After Transplantation

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only